Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CFTR | P13569 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | GNG2 | P59768 | 1/20 | 0.45 |
| ▸ | GNB1 | P62873 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | CASP1 | P29466 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11320359 | 0.88 | GNG2 (0.53) | TDP1MAPTPOLBCFTRKMT2A | |
| SCHEMBL9136264 | 0.87 | GPR35 (0.53) | TDP1MAPTPOLBCFTRKMT2A | |
| SCHEMBL2081736 | 0.86 | TDP1 (0.57) | TDP1MAPTPOLBKMT2AMEN1 | |
| SCHEMBL30483162 | 0.86 | TDP1 (0.57) | TDP1MAPTPOLBKMT2AMEN1 | |
| SCHEMBL6827233 | 0.86 | KIF11 (0.52) | TDP1MAPTPOLBCFTRALOX15 | |
| SCHEMBL1654638 | 0.84 | ALDH1A1 (0.55) | TDP1MAPTPOLBKMT2AMEN1 | |
| SCHEMBL1504525 | 0.84 | NPC1 (0.60) | MAPTPOLBKMT2AMEN1NPC1 | |
| SCHEMBL11212757 | 0.83 | MAPT (0.47) | TDP1MAPTPOLBCFTRKMT2A | |
| SCHEMBL31314406 | 0.83 | SMN1; SMN2 (0.52) | TDP1MAPTPOLBCFTRKMT2A | |
| SCHEMBL10782684 | 0.83 | SMN1; SMN2 (0.52) | TDP1MAPTPOLBCFTRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4178455-A | FROM AROMATIC NITRO COMPOUND, ALCOHOL AND CARBON MONOXIDE | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1979-12-11 | — | — | US | claimed |
| WO-2024158872-A1 | 1,3-INDOLE-PROPANAMIDE INHIBITORS OF SARS-COV-2 PLPRO/NSP3 AND DERIVATIVES THEREOF | THE ROCKEFELLER UNIVERSITY (US) | 2024-08-02 | — | — | WO | disclosed |
| WO-2023247593-A1 | PYRROLOPYRIDINE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023183470-A1 | MODULATORS OF PROTEIN KINASES | VIBLIOME THERAPEUTICS, LLC (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023283369-A1 | MODULATORS OF PROTEIN KINASES | VIBLIOME THERAPEUTICS, LLC (US) | 2023-01-12 | — | — | WO | disclosed |
| EP-2184285-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-11-04 | — | — | EP | disclosed |
| US-7863440-B2 | Macrocyclic carbodiimides (MC-CDI) and their derivatives, syntheses and applications of the same | GREAT EASTERN RESINS INDUSTRIAL CO., LTD. (TW) | 2011-01-04 | — | — | US | disclosed |
| EP-2184285-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-05-12 | — | — | EP | disclosed |
| US-20090163525-A1 | SUBSTITUTED QUINAZOLINES WITH ANTI-CANCER ACTIVITY | ASTRAZENECA AB (SE) | 2009-06-25 | — | — | US | disclosed |
| US-20090118261-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| EP-1761506-A1 | SUBSTITUTED QUINAZOLONES AS ANTI-CANCER AGENTS | AstraZeneca AB (SE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006040568-A1 | QUINOXALINES AS B RAF INHIBITORS | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006024834-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | disclosed |
| WO-2005123696-A1 | SUBSTITUTED QUINAZOLONES AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2005-12-29 | — | — | WO | disclosed |
| EP-0000563-B1 | PROCESS FOR PREPARING AROMATIC URETHANES | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1982-05-12 | — | — | EP | disclosed |
| EP-0000815-B1 | PROCESS FOR PREPARING N-ARYL OR N-ARALKYL SUBSTITUTED URETHANES | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1982-01-27 | — | — | EP | disclosed |
| US-4227008-A | CATALYTIC REACTION OF A NITRO-, NITROSO-, OR CARBAMATE-CONTAINING AROMATIC PRIMARY AMINE, AN ALCOHOL, AND CARBON MONOXIDE | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1980-10-07 | — | — | US | disclosed |
| US-4178455-A | FROM AROMATIC NITRO COMPOUND, ALCOHOL AND CARBON MONOXIDE | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1979-12-11 | — | — | US | disclosed |
| EP-0000815-A1 | Process for preparing N-aryl or N-aralkyl substituted urethanes | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1979-02-21 | — | — | EP | disclosed |
| EP-0000563-A1 | Process for preparing aromatic urethanes | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1979-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118261-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | TDP1 2243/4885MAPT 4337/4885POLB 2028/4885 |
| US-20090163525-A1 | SUBSTITUTED QUINAZOLINES WITH ANTI-CANCER ACTIVITY | BRAF, NRAS, RAF1 | TDP1 1677/4885MAPT 4546/4885POLB 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.